Drawing for A

USPTO serial 79139640

A

Reviewed by CopyMark Law Group

Reg. 4619191Status 706Registered
Filing date
Status date
Registration date
Oct 14, 2014
Examiner
LAVACHE, LINDA M
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with A?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffery A. Smith

Jeffery A. Smith MILLEN WHITE ZELANO & BRANIGAN, P.C.2200 Clarendon BoulevardSuite 1400Arlington, VA, 22201

Goods and services

ClassDescriptionStatusFirst use
005[ In vitro diagnostic preparations for medical use; diagnostic test reagents for medical use; chemical reagents for medical or veterinary use; diagnostic reagents and contrast media agents for medical use; Medical diagnostic reagents; Reagents for medical use ]SECTION 71 - CANCELLED—
009[ Measuring apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometry analyzers for cellular analysis; scientific, optical, measuring, signaling and checking apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometers for single cell and population based cellular analysis; measuring and testing machines and instruments, namely, protein separation and isolation instruments, flow cytometers, and laboratory liquid handlers and automation for testing and implementing cellular based screening methods; laboratory apparatus and instruments for use in growing, maintaining, evaluating and quality control of cell cultures, automated liquid dispensing, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purposes; chemistry apparatus and instruments for maintaining, evaluating and quality control of cell cultures, automated liquid dispensing of compound preparations and chemical reagents, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purpose ]SECTION 71 - CANCELLED—
042Scientific research and development; [ scientific and technological services, namely, novel multi-parametric phenotypic screening in the nature of analytical testing services and protein isolation for the characterization and simultaneous identification of multiple biological and physiological effects caused by drug candidates on live human cell models in the field of pharmaceutical research, drug discovery and characterization of compound effect, and scientific research and development relating thereto; ] Scientific and technological services for scientific analysis, testing and research in the fields of pharmaceutical research, [ drug discovery and characterization of compound effect, and protein separation, isolation and characterization; ] scientific research services; scientific testing and analysis in the fields of pharmaceutical research, [ drug discovery and characterization of compound effect, and protein separation, isolation and characterization; ] computer-assisted scientific research, testing and analysis services in the fields of pharmaceutical research, drug discovery and characterization of compound effect by using mathematical and statistical algorithms to compare and predict the effect of a target compound to that of an approved drug or known toxin, where a biological fingerprint is created and analyzed by measuring the broad physiological and biological effect of said compounds on live human cells; laboratory research and analysis services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, [ and protein separation, isolation and characterization; pharmaceutical research and development; ] Scientific research and scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, [ and protein separation, isolation and characterization; ] scientific laboratory services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, [ and protein separation, isolation and characterization; ] scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery [ and characterization of chemical compounds, and protein separation, isolation and characterization; provision of information about medical and scientific research in the field of pharmaceuticals; preparation of reports on scientific research ]; provision of scientific information on technological research in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; [ provision of scientific information about industrial analysis and research services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; provision of information and data relating to medical research and development and veterinary medical research; consultancy services in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; engineering and ] scientific consultancy services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization; provision of technical advice in the field of scientific and industrial research; consultancy in the field of scientific and industrial research ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 10, 2026INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Sep 9, 2025NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Sep 9, 202571AGREGISTERED-SEC.71 ACCEPTED—
Aug 13, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 11, 2025PC.DPETITION TO DIRECTOR DISMISSED—
Aug 11, 2025APETASSIGNED TO PETITION STAFF—
Apr 14, 2025TPDRTEAS PETITION TO DIRECTOR RECEIVED—
Oct 14, 2023REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Sep 29, 2023RNWLINTERNATIONAL REGISTRATION RENEWED—
Jun 7, 2023LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Mar 27, 2023LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Sep 20, 2022INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Aug 3, 2022INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Aug 3, 2022INPCINVALIDATION PROCESSED—
Apr 30, 2022INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 30, 2021NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Aug 30, 2021C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.—
Aug 27, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 14, 2021ES75TEAS SECTION 71 & 15 RECEIVED—
Oct 14, 2019REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Apr 24, 2015FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 11, 2015FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 11, 2015FIMPFINAL DISPOSITION PROCESSED—
Jan 14, 2015FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 14, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 31, 2014ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Jul 29, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 29, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 24, 2014GPNXNOTIFICATION PROCESSED BY IB—
Jul 9, 2014OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 9, 2014OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 9, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 26, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 25, 2014ALIEASSIGNED TO LIE—
Jun 9, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 9, 2014XAECEXAMINER'S AMENDMENT ENTERED—
Jun 9, 2014GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 9, 2014GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 9, 2014CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 4, 2014ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 4, 2014REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 22, 2014RFNTREFUSAL PROCESSED BY IB—
Feb 6, 2014RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 6, 2014RFRRREFUSAL PROCESSED BY MPU—
Feb 6, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 5, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 31, 2014DOCKASSIGNED TO EXAMINER—
Dec 17, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 13, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 12, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance